Li Song

Li Song

Auto-generated profile, based on publicly available information

Li Song

College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
LSLi Song
Li Song
WZWei Zhang
Wei Zhang
STShi-Yun Tang
Shi-Yun Tang
SLSi-Min Luo
Si-Min Luo
PXPei-Yu Xiong
Pei-Yu Xiong
WHWei Huang
Wei Huang
Renal fibrosis (RF) is the end stage of several chronic kidney diseases. Its series of changes include excessive accumulation of extracellular matrix, epithelial-mesenchymal transition (EMT) of renal tubular cells, fibroblast activation, immune cell infiltration, and renal cell apoptosis. RF can eventually lead to renal dysfunction or even renal failure. A large body of evidence suggests that natural products in traditional Chinese medicine (TCM) have great potential for treating RF. In this article, we first describe the recent advances in RF treatment by several natural products and clarify their mechanisms of action. They can ameliorate the RF disease phenotype, which includes apoptosis, endoplasmic reticulum stress, and EMT, by affecting relevant signaling pathways and molecular targets, thereby delaying or reversing fibrosis. We also present the roles of nanodrug delivery systems, which have been explored to address the drawback of low oral bioavailability of natural products. This may provide new ideas for using natural products for RF treatment. Finally, we provide new insights into the clinical prospects of herbal natural products.

15 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
LSLi Song
Li Song
XZXianbin Zhao
Xianbin Zhao
SLSimin Luo
Simin Luo
STSongqi Tang
Songqi Tang
WHWei Huang
Wei Huang
JGJinlin Guo
Jinlin Guo
To investigate whether astragaloside IV (AS IV) reverses epithelial–mesenchymal transition (EMT) in renal tubular epithelial cells in diabetic kidney disease (DKD) by regulating LAMA5 to inhibit Notch signaling.A DKD model was established using db/db mice. Differentially expressed genes were screened by bulk RNA-seq combined with DESeq2, followed by GO-BP enrichment analysis. GEO datasets were subgrouped by median LAMA5 expression, and GSEA was used to analyze the relationship between LAMA5 and Notch/EMT pathways. In high glucose (HG)-induced HK-2 cells, LAMA5 and Notch1 were overexpressed or silenced, and Notch pathway molecules (Notch1, Snail, Slug, Twist) and EMT markers (E-cadherin, N-cadherin, Fibronectin, Vimentin) were detected. Forward and reverse gene intervention experiments were performed to verify the target of AS IV. AS IV reduced BUN, CRE, MAU, and UP levels and alleviated renal tubular injury and interstitial fibrosis in DKD mice. LAMA5 was upregulated in DKD and decreased after AS IV intervention, with differentially expressed genes enriched in the Notch pathway. GEO analysis showed EMT was significantly upregulated in DKD samples with high LAMA5 expression. In HK-2 cells, LAMA5 overexpression upregulated Notch1, NICD1, Snail, Slug, and Twist, while silencing LAMA5 inhibited them. AS IV downregulated Notch molecules and reversed EMT in vivo and in vitro. Forward and reverse intervention confirmed that AS IV's anti-EMT effect depends on LAMA5 downregulation. AS IV reverses EMT in DKD renal tubular epithelial cells by downregulating LAMA5 to inhibit abnormal Notch activation. This study is the first to reveal the function of the "LAMA5–Notch–EMT" axis in DKD tubular injury.